HC Wainwright Predicts Higher Earnings for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Research analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Zenas BioPharma in a research note issued on Friday, August 14th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($1.31) for the quarter, up from their prior estimate of ($1.46). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Zenas BioPharma’s current full-year earnings is ($5.12) per share. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2026 earnings at ($1.31) EPS, FY2026 earnings at ($5.83) EPS, FY2027 earnings at ($5.11) EPS, FY2028 earnings at ($3.42) EPS, FY2029 earnings at ($2.72) EPS and FY2030 earnings at ($1.93) EPS.

Several other brokerages have also weighed in on ZBIO. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Zenas BioPharma in a research note on Friday. Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Finally, Wedbush reissued an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Zenas BioPharma currently has a consensus rating of “Moderate Buy” and an average price target of $45.71.

Zenas BioPharma Price Performance

Shares of ZBIO opened at $30.50 on Tuesday. The company has a debt-to-equity ratio of 1.57, a current ratio of 9.93 and a quick ratio of 9.93. The company has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.39 and a beta of -1.03. The business’s 50-day moving average is $27.21 and its 200-day moving average is $23.48. Zenas BioPharma has a fifty-two week low of $13.50 and a fifty-two week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Wednesday, August 12th. The company reported ($1.77) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The company had revenue of $1.00 million for the quarter, compared to analyst estimates of $15.00 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZBIO. Quarry LP grew its stake in shares of Zenas BioPharma by 34.5% in the third quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after acquiring an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Zenas BioPharma during the 3rd quarter worth about $30,000. GF Fund Management CO. LTD. bought a new position in shares of Zenas BioPharma during the 4th quarter worth about $38,000. Quantbot Technologies LP acquired a new position in shares of Zenas BioPharma during the second quarter valued at about $49,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after buying an additional 1,716 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.